World Congress of Cardiology 2014, a major scientific event in global medicine, took place in Melbourne, Australia from 4-7 May 2014. The Congress was organized by the World Heart Federation and co-hosted by the Cardiac Society of Australia and New Zealand and the National Heart Foundation of Australia. The international forum is annually held in different countries throughout the world and serves as a global platform for cardiovascular disease professionals to share knowledge and network with their peers.
This year world leading experts presented their reports at 150 scientific sessions on cardiology and public health organization, over 1000 lectures were delivered. The scientific programme is compiled by a special WCC Scientific Programme Committee, which is made up of 4 co-chairs, 11 ex officio delegates, 40 Topic Group Leaders and 146 Topic Group Experts from around the world. The Committee selects the best abstracts, satisfying all modern requirements.
Ten papers of Tyumen Cardiology Center’s scientists were deemed worthy of being presented at the Congress. Professor Vadim Kuznetsov, Director of Tyumen Cardiology Center, Honored Scientist of the Russian Federation delivered 2 oral and 8 poster presentations. One of his lectures – “Influence of atrioventricular junction ablation on survival of patients with congestive heart failure and atrial fibrillation receiving cardiac resynchronization therapy in real clinical practice” – was presented at the symposium “Cardiac Resynchronization Therapy in 2014”.
The scientific programme of the Congress includes the following topics: arrhythmias, cardiac valvular disease, ischaemia, hypertension, epidemiology and prevention, health promotion advocacy, basic science, cardiac imaging, paediatrics, rheumatic heart disease and nursing.
The World Health Federation is dedicated to leading the global fight against cardiovascular disease via uniting the community of more than 200 member organizations and the World Health Organization. The World Heart Federation aligns its efforts around the World Health Organization’s related target of reducing premature CVD mortality by 25% by 2025.
